SparingVision is a biotechnology company focused development of genomic medicines for the treatment of blinding inherited retinal diseases. Founded in 2016, SparingVision is backed by investors that include Bpifrance, Foundation Fighting Blindness, Ysios Capital, Jeito Capital, and 4BIO Capital and is headquartered in Paris.